Effect of L-carnitine on quality of life in covert hepatic encephalopathy: a randomized, doubleblind, placebo-controlled study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: L-carnitine is potentially beneficial in patients with hepatic encephalopathy (HE). We aimed to evaluate the impact of L-carnitine on the quality of life and liver function in patients with liver cirrhosis and covert HE. Methods: We conducted an investigator-initiated, prospective, multi-center, double-blind, randomized phase III trial in patients with covert HE. A total of 150 patients were randomized 1:1 to L-carnitine (2 g/day) or placebo for 24 weeks. Changes in quality of life and liver function were assessed at 6 months. The model for end-stage liver disease (MELD), the 36-Item Short Form Survey (SF-36), the psychometric hepatic encephalopathy score (PHES), and the Stroop Test were evaluated in all patients. Results: The total SF-36 score significantly improved in the L-carnitine group after 24 weeks (difference: median, 2; interquartile range, 0 to 11; p < 0.001); however, these values were comparable between the two groups. Furthermore, there was a significant ordinal improvement in PHES scores among patients with minimal HE who were in the L-carnitine group (p = 0.007). Changes in the total carnitine level also positively correlated with improvements in the Stroop test in the L-carnitine group (color test, r = 0.3; word test, r = 0.4; inhibition test, r = 0.5; inhibition/switching test, r = 0.3; all p < 0.05). Nevertheless, the MELD scores at week 24 did not differ between the groups. Conclusions: Twenty-four weeks of L-carnitine supplementation was safe but ineffective in improving quality of life and liver function.
Abstract
Background/Aims: L-carnitine is potentially beneficial in patients with hepatic encephalopathy (HE). We aimed to evaluate the impact of L-carnitine on the quality of life and liver function in patients with liver cirrhosis and covert HE. Methods: We conducted an investigator-initiated, prospective, multi-center, double-blind, randomized phase III trial in patients with covert HE. A total of 150 patients were randomized 1:1 to L-carnitine (2 g/day) or placebo for 24 weeks. Changes in quality of life and liver function were assessed at 6 months. The model for end-stage liver disease (MELD), the 36-Item Short Form Survey (SF-36), the psychometric hepatic encephalopathy score (PHES), and the Stroop Test were evaluated in all patients. Results: The total SF-36 score significantly improved in the L-carnitine group after 24 weeks (difference: median, 2; interquartile range, 0 to 11; p < 0.001); however, these values were comparable between the two groups. Furthermore, there was a significant ordinal improvement in PHES scores among patients with minimal HE who were in the L-carnitine group (p = 0.007). Changes in the total carnitine level also positively correlated with improvements in the Stroop test in the L-carnitine group (color test, r = 0.3; word test, r = 0.4; inhibition test, r = 0.5; inhibition/switching test, r = 0.3; all p < 0.05). Nevertheless, the MELD scores at week 24 did not differ between the groups. Conclusions: Twenty-four weeks of L-carnitine supplementation was safe but ineffective in improving quality of life and liver function.
참고문헌 (23)
- Flud CR, "Prognostic implications of minimal", covert hepatic encephalopathy : large-scale validation cohort studies, 2019, pp.9, 112~116
- Vilstrup H, "Hepatic encephalopathy in chronic liver disease : 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver", Hepatology, 60, pp.715~735 (2014)
- Roman E, "Minimal hepatic encephalopathy is associated with falls", Am J Gastroenterol, 106, pp.476~482 (2011)
- Patidar KR, "Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization", Am J Gastroenterol, 109, pp.1757~1763 (2014)
- Bajaj JS, "Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents : a cost-effectiveness analysis", Hepatology, 55, pp.1164~1171 (2012)
- Jun DW, "Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction", Liver Int, 31, pp.1315~1324 (2011)
- Morris AJ, "Postnastal changes in the concentration of carnitine and acylcarnitines in the rat brain", Brain Res, 284, pp.381~384 (1983)
- Hassan A, "Effects of oral L-carnitine on liver functions after transarterial chemoembolization in intermediate-stage HCC patients", Mediators Inflamm, 2015, pp.608216~ (2015)
- Bae JC, "Improvement of nonalcoholic fatty liver disease with carnitine-orotate complex in type 2diabetes(CORONA) : a randomized controlled trial", Diabetes Care, 38, pp.1245~1252 (2015)
- 전대원, "Efficacy and safety of entecavir plus carnitine complex (GODEXⓇ) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study", Clinical and Molecular Hepatology, 19(2), pp.165~172 (2013), 대한간학회[DOI]
- Malaguarnera M, "Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy : a randomized and controlled clinical trial", Metab Brain Dis, 26, pp.281~289 (2011)
- Malaguarnera M, "Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy : a randomized, double-blind, placebo-controlled study", Am J Clin Nutr, 93, pp.799~808 (2011)
- Malaguarnera M, "Branched chain amino acids supplemented with L-acetylcarnitine versus BCAA treatment in hepatic coma : a randomized and controlled double blind study", Eur J Gastroenterol Hepatol, 21, pp.762~770 (2009)
- Malaguarnera M, "Effects of L-acetylcarnitine on cirrhotic patients with hepatic coma : randomized double-blind, placebo-controlled trial", Dig Dis Sci, 51, pp.2242~2247 (2006)
- Malaguarnera M, "Acetyl-L-carnitine treatment in minimal hepatic encephalopathy", Dig Dis Sci, 53, pp.3018~3025 (2008)
- Malaguarnera M, "Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy", Scand J Gastroenterol, 46, pp.750~759 (2011)
- Yoon EL, "Validation of the Korean Stroop Test in diagnosis of minimal hepatic encephalopathy", Sci Rep, 9, pp.8027~ (2019)
- Seo YS, "Psychometric hepatic encephalopathy score for the detection of minimal hepatic encephalopathy in Korean patients with liver cirrhosis", J Gastroenterol Hepatol, 27, pp.1695~1704 (2012)
- Askarpour M, "Effect of L-carnitine supplementation on liver enzymes : a systematic review and meta-analysis of randomized controlled trials", Arch Med Res, 51, pp.82~94 (2020)
- Fuller RK, "Elevated plasma carnitine in hepatic cirrhosis", Hepatology, 3, pp.554~558 (1983)
- D’Arienzo A, "Hypercarnitinemia in cirrhosis", Hepatology, 5, pp.343~ (1985)
- Saito M, "Serum level of taurine would be associated with the amelioration of minimal hepatic encephalopathy in cirrhotic patients", Hepatol Res, 46, pp.215~224 (2016)
- Abbasnezhad A, "Effect of L-carnitine on liver enzymes and biochemical factors in hepatic encephalopathy : a systematic review and meta-analysis", J Gastroenterol Hepatol, 34, pp.2062~2070 (2019)